REFERENCES

1. Ingelman- Sunderberg M. (2004), Phamacogenetics of Cytochrome P450 and its applications in drug therapy: the past, present and future. *Trends Pharmacol Sci.*; 25(4):193-200.
2. Wilkinson GR. (2005), Drug metabolism and variability among patients in drug response. *N Engl J Med*.; 352:2211–2221.
3. Slaughter RL, Edwards DJ. (1995), Recent advances: the cytochrome P450 enzymes. *Ann Pharmacother*.; 29:619–624.
4. Evans WE, Relling MV. (1999), Pharmacogenimics: translating functional genomics into rational therapeutics. *Science.*; 286:487-491.
5. Lennard MS. (1990), Genetic Polymorphism of sparteine/debrisoquine oxidation: A reappraisal. *Pharmacol Toxicol*; 67:273-283.
6. Nebert DW. (1997), Pharmacogenetics: 65 candles on the cake. *Pharmacogenetics.*; 7:435-440.
7. Wilkinson GR. (2005), Drug metabolism and variability among patients in drug response. *N Engl J Med*.; 352:2211–2221
8. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. (2001), Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. *JAMA*.; 286:2270–2279.
9. Bradford LD. (2002), CYP2D6 allele frequency in European caucasians, Asians, Africans, and their descendants. *Pharmacogenomics*.; 3:229–43.
10. Special report: (2004), genotyping for cytochrome P450 polymorphisms to determine drug-metabolizer status. *Technol Eval Cent Asses Program Exec Summ*.; 19:1–2.
11. Abraham BK, Adithan C. (2001), Genetic polymorphism of CYP2D6. *Indian J Pharmacol*.; 33:147–69.
12. Bernard S, Neville KA, Nguyen AT, Flockhart DA. (2006), Inter-ethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. *Oncologist*.; 11:126–35.
13. Chong E, Ensom MH. (2003), Pharmacogenetics of the proton pump inhibitors: a systematic review. *Pharmacotherapy*.; 23:460–71.
14. Weinshilboum R. (2003), Inheritance and drug response. *N Engl J Med*.; 348:529–37.

15. Linder MW, Prough RA, Valdes R. (1997), Jr. Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. *Clin Chem*.; 43:254-266.
16. Kroemer HK, Eichelbaum M. (1995), "it's the genes stupid" molecular basis and clinical consequences of Cytochrome P450 2D6 polymorphism. *Life Sci*.; 56:2285-2298.
17. Hou ZY, Pickle LW, Mayer SP. (1991), Woosley RL. () Salivary analysis for determination fo dextromethorphan metabolic phenotype. *Clin Pharmacol Ther.*; 49:410-419.
18. Hou ZY, Chen CP, Yang WC, Lai MD, Buchert ET, Chung GM et al. (1996), determination of dexromethorphan metabolic phenotype by salivary analysis with a reference to genotype in Chinese patients receiving renal hemodialysis. *Clin Pharmacol Ther.*; 59:411-417.
19. Du Souich P, McLean AJ, Stoeckel K, Ohlendorf D, Gibaldi M. (1979)Screening methods using sulfamethazine for determining acetylator phenotype. Clin Pharmacol The. Dec; 26(6):757-65.
20. Chapron CJ, Blum MR.(1976) Relationship of sulfamethazine disposition kinetics to acetylator phenotype in man. A preliminary study. J Clin Pharmacol.16(7):338-44.
21. Adam A.M, H J Rogers, S A Amiel, and R D Rubens.(1984) The effect of acetylator phenotype on the disposition of aminoglutethimide. Br J Clin Pharmacol. October; 18(4): 495–505.
22. Iyer, Federico Innocenti, Lalitha and Mark J. Ratain.(2001) Pharmacogenetics of Anticancer Agents: Lessons from Amonafide and Irinotecan. Copyright by The American Society for Pharmacology and Experimental Therapeutics. DMD 29:596–600,
23. Ahmad, R. A., Rogers, H. J., Vandenburg, M. & Wright, P. (1981). Effects of concurrent administration of other substrate of N-acetyltransferase on dapsone acetylation. Br. J. clin. Pharmac., 12, 83-86
24. Philip P.A. M. S. Robert2 & H. J. Rogers,(1984) A rapid method for determination of acetylation phenotype using dapsone. Br. J. clin. Pharmac. 17, 465-469.
25. Zacest R, Gilmore E, Koch-Weser J:(1972) Treatment of essential hypertension with combined vasodilation and bcta-adrcnergic blockade. N Engl J Med , 617,

26. Shepherd A.M, JL McNay, TM Ludden, MS Lin and GE Musgrave,(1981) Plasma concentration and acetylator phenotype determine response to oral hydralazine.Hypertension, 3:580-585.
27. Grant D.M,B.K.Tang & W.Calou,(1984) A Simple test for acetylator phenotype using caffeine,Department of pharmacology,University of torranto,Canada M5S1A8. Br. J. clin. Pharmac.17, 459-464
28. Irving W.W. et al,(1998) elisa kit rapid determination of N-acetyltransferase(NAT2) phenotypes.US005830672A.
29. Thamann et al(2002) Novel sequence variento of the human N-acetyltransferasc-2(NAT-2) Gene and use their of.US0020020128215
30. Mayers A.(2004) Pharmacogenetics – five decades of therapeutic lesion from genetic diversity, ,vol-5,669.
31. David w. hein,Charlene A.Mcqueen,Denis M.Grant,(2000)pharmacogenetics of arylamine N-acetyatransferase:A symposium in honour Wendell w.webervol 28,1425-1432
32. Joanna E. Summerscales and P. David Josephy,(2004) Human Acetyl CoA:Arylamine *N*-Acetyltransferase Variant Generated by Random Mutagenesis,vol 65,(220-226),
33. Charuvind K. Awale, R. Mayee,(2011)Acetylator Phenotype in drug metabolism Relevant to Pharmacogenomics and Pharmacogenetics Sciences, International Journal of Pharmacy Research & Technology, 2011, Volume 1, Issue 2, 08-11.
34. Hoirun Nisa, Suminori Kono, Guang Yin,et al(2010)Cigarette smoking, genetic polymorphisms andcolorectal cancer risk: the Fukuoka Colorectal Cancer StudyNisa *et al. BMC Cancer,* 10:274
35. Umar Farooq**,** N. Malla & M.L. Dubey(2009) Genetic polymorphism in *msp-2*, *ama-1* and *csp* genes in *Plasmodium falciparum* field isolates from north and north-western Indi*J Vector Borne Dis* 46, pp. 109–116,
36. Gupta V.K, Ashok. K. Misra,Gaur, Pandey and ,U.K.Chauhan(2009) Studies of genetic polymorphism in the isolates of *Fusarium solani, Australian Journal of Crop Science* Southern Cross Journals,*3(2):101-106*

37. Junji Saruwatari ,Takateru Ishitsu and Kazuko Nakagawa(2010) Update on the Genetic Polymorphisms of Drug-Metabolizing Enzymes in Antiepileptic Drug Therapy, *Pharmaceuticals* 2010, *3*, 2709-2732;

Submitted By
Mr. Deepak S. Sid
Research Scholar
Reg. No.:

Under the able Guidance of
Dr. Ashish Gawai
Dr. VedPrakash Patil Pharmacy College,
Georai Tanda, Aurangabad (MS)